Details of the Drug Formulations

General Information of Drug (ID: DMPWGBR)

Drug Name
TRICLABENDAZOLE Drug Info
Synonyms
Triclabendazole; 68786-66-3; Fasinex; 6-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazole; C14H9Cl3N2OS; Triclabendazolum [INN-Latin]; Triclabendazol [INN-Spanish]; CCRIS 8988; UNII-4784C8E03O; CGA 89317; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole; CPD000466357; MLS001424101; CHEMBL1086440; 6-Chloro-5-(2,3-dichlorophenoxy)-2-methylthio-benzimidazole; 4784C8E03O; NCGC00164610-01; Triclabendazole, 98%; SMR000466357; AK-68238; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazole
Indication
Disease Entry ICD 11 Status REF
Helminth infection 1F90.0 Approved [1]
Cross-matching ID
PubChem CID
50248
ChEBI ID
CHEBI:94759
CAS Number
68786-66-3
TTD ID
D02VMJ
INTEDE ID
DR1639
ACDINA ID
D01502

Full List of Drug Formulations Containing This Drug

Triclabendazole 250 mg tablet
Company Formulation ID FDA Description
Novartis Pharmaceuticals Corporation F23315 Colloidal Silicon Dioxide; Iron Oxide Red; Lactose Monohydrate; Maize Starch; Magnesium Stearate; Methylhydroxyethylcellulose
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015